Ascletis Oral GLP-1 ASC30 Cuts HbA1c 1.7% vs Placebo in 12 Weeks
Phase II U.S. study of 100 T2D patients: once-daily oral ASC30 lowered HbA1c 1.6–1.7% vs placebo and weight 3.8–4.4%, no liver signal.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Ascletis Pharma has reported Phase II results for ASC30, an oral small-molecule GLP-1 drug. According to TradingView, citing a PR Newswire press release, the 100-patient U.S. trial in adults with type 2 diabetes showed HbA1c falling 1.6–1.7% against placebo after 12 weeks, while body weight dropped 3.8–4.4% after 13 weeks.
The drug was well tolerated, with no gastrointestinal adverse events leading to discontinuation and no signal of liver harm. Because the tablet is taken once daily, it offers an alternative to injectable rivals.
The next major milestone is a Phase III obesity study that is still enrolling, with data expected in Q3 2028 and a possible regulatory filing in 2028.
why it matters
For markets, this confirms efficacy and tolerability at a mid-stage of development rather than a breakthrough. A significant re-rating would likely require larger and longer Phase III diabetes data or convincing obesity results.
tags
instruments
sources
- Ascletis Pharma Inc. Oral GLP-1 Cuts HbA1c 1.7% Vs Placebo at 12 Weeks — TradingView, 28 October 2026 at 23:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗